Faricimab, sold under the brand name Vabysmo, is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and...
20 KB (1,543 words) - 06:38, 10 March 2024
Drusen, is in preparation. Ranibizumab, aflibercept, brolucizumab, and faricimab are approved VEGF inhibitors for the treatment of CNV in wet AMD. All...
90 KB (9,840 words) - 07:29, 23 May 2024
mouse CD15 appendicitis (diagnosis) Faralimomab mab mouse IFN receptor Faricimab Vabysmo mab humanized VEGF-A and Ang-2 Y angiogenesis, ocular vascular...
135 KB (4,013 words) - 03:57, 1 June 2024
S01LA06 Brolucizumab S01LA07 Abicipar pegol S01LA08 Bevacizumab S01LA09 Faricimab S01XA01 Guaiazulene S01XA02 Retinol S01XA03 Sodium chloride, hypertonic...
10 KB (800 words) - 03:10, 20 April 2024
approved by the US FDA: blinatumomab, emacizumab, amivantamab, tebentafusp, faricimab, teclistamab, mosunetuzumab, epcoritamab, glofitamab. Among the bsAb programs...
29 KB (3,308 words) - 18:16, 18 March 2024